REVIEW

Progressive Multifocal Leukoencephalopathy [version 1; peer review: 2 approved]

Laura Adang¹, Joseph Berger²

¹Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA

²Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA

V1 First published: 10 Dec 2015, 4(F1000 Faculty Rev):1424
<https://doi.org/10.12688/f1000research.7071.1>

Latest published: 10 Dec 2015, 4(F1000 Faculty Rev):1424
<https://doi.org/10.12688/f1000research.7071.1>

Abstract

Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease with significant morbidity and mortality and no effective, targeted therapies. It is most often observed in association with abnormalities of cell-mediated immunity, in particular human immunodeficiency virus (HIV) infection, but also occurs in association with lymphoproliferative diseases, certain immunosuppressive and immunomodulatory regimens, and other conditions. The etiologic agent of PML is a small, ubiquitous polyomavirus, the JC virus (JCV, also known as JCPyV), for which at least 50% of the adult general population is seropositive. PML results when JCV replicates within cerebral oligodendrocytes and astrocytes, leading to oligodendrocyte death and demyelination. Unfortunately, no treatments have been convincingly demonstrated to be effective, though some have been employed in desperation; treatment otherwise includes attempts to restore any immune system defect, such as the withdrawal of the causative agent if possible, and general supportive care.

Keywords

Progressive multifocal leukoencephalopathy , demyelination , JC virus , immunocompromised , highly active antiretroviral therapy

Open Peer Review

Approval Status

	1	2
version 1
10 Dec 2015		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Stephen G. Waxman**, Yale University, New Haven, USA
2. **Meena Subramanyam**, Biogen Idec, Cambridge, USA
Ellen Cahir-McFarland, Biogen Idec, Cambridge, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Laura Adang (adangl@email.chop.edu)

Competing interests: Laura Adang declares that she has no competing interests. Joseph R. Berger is or has been a consultant to the following companies: Genentech, Genzyme, Incyte, Inhibikase, Johnson & Johnson, and Novartis. He serves or has served on the PML Adjudication Committees of the following companies: Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Millennium, PAREXEL, Pfizer, Roche, and Takeda.

Grant information: Joseph R. Berger has received grants from the PML Consortium and Biogen Idec.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2015 Adang L and Berger J. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Adang L and Berger J. **Progressive Multifocal Leukoencephalopathy [version 1; peer review: 2 approved]** F1000Research 2015, 4(F1000 Faculty Rev):1424 <https://doi.org/10.12688/f1000research.7071.1>

First published: 10 Dec 2015, 4(F1000 Faculty Rev):1424 <https://doi.org/10.12688/f1000research.7071.1>

Introduction

Progressive multifocal leukoencephalopathy (PML), a typically rapidly progressive, potentially fatal neurologic syndrome, was first described in 1958 as a complication of chronic lymphocytic leukemia and Hodgkin's disease¹. Within two decades of its initial description, in the 1970s, the JC virus (JCV, also known as JCPyV) was discovered as the etiologic agent². It is named for a subject with PML – patient John Cunningham³. Due to its rarity (1.3 cases per 1000 person-years at risk in human immunodeficiency virus [HIV]+ patients), the disorder is regarded as an orphan disease⁴. However, following the acquired immunodeficiency syndrome (AIDS) pandemic and with newer immunomodulatory therapies, such as natalizumab, that predispose to the development of PML, the incidence of the disease has increased substantially.

The JC Virus

A ubiquitous infection, the JCV infects over half of the adult population globally^{3,5,6}. Typically the initial exposure occurs during childhood. As no identified clinical illness accompanies acute infection, it is believed that initial infection results in a transient asymptomatic viremia following which the virus establishes as a latent or persistent infection in the kidney and perhaps elsewhere in the body³. The JCPyV found in the urine of approximately one-third of all adults is referred to as the archetype virus and is incapable of replicating effectively in glial tissue. It is theorized that the archetypal form of the virus is responsible for the primary infection. The mode of transmission is also unclear, although it is suspected to be through the tonsils or gastrointestinal tract³. Interestingly, even among the immunocompromised, only a small subset of infected patients develop PML, as the development of this syndrome requires a complex series of events: the virus must be transformed to the prototype (neurotropic) virus, seed the brain, and avoid neuro-immunosurveillance and clearance. Generally, this occurs in the setting of an impairment in cell-mediated immunity, as with HIV/AIDS, or with the use of immunomodulatory agents, such as natalizumab. The transformation of JCV from the archetype to the prototype virus requires genetic modifications in the non-coding control region of the viral DNA. This transformation of the small, circular JCPyV DNA genome impacts the replicative ability, gene transcription patterns, and homing within the body, and ultimately disease pathology³.

PML and the JC virus

In immunocompetent individuals, the JCV is rarely pathogenic, but in immunocompromised patients, it may cause PML, an aggressive, progressive neurologic syndrome that is potentially devastating. Prior to the availability of highly active antiretroviral therapy (HAART), PML was observed in 5–10% of all persons with AIDS, and HIV/AIDS has been an underlying predisposing cause of PML in more than one-half of individuals^{3,7}. Following the advent of HAART, the incidence of PML in this population has declined⁶. Another cluster of PML cases is observed in patients receiving immunomodulatory therapies. Two therapies in particular appear to predispose to PML, namely natalizumab (trade name Tysabri) and efalizumab (now off the market)⁸. However, PML has been reported with the use of rituximab, belatacept, fingolimod, infliximab, alemtuzumab, mycophenolate mofetil, fludarabine, leflunomide, and fumaric acid esters as well⁹. The increased risk of PML from natalizumab is thought to be due to the known mechanism of

the drug, namely $\alpha 4 \beta 1$ integrin binding. In so doing, this monoclonal antibody prevents lymphocytes from binding to vascular cell adhesion molecule 1 (VCAM) on the central nervous system (CNS) endothelium, decreasing CNS immune surveillance¹⁰. While an immune-modulated state is relatively common, PML remains a rare disorder even within these subpopulations. This suggests that immunosuppression alone is insufficient to reactivate the JCV and cause disease.

While the JCV predominantly results in the clinical syndrome of PML, it can also cause granule cell neuronopathy (GCN), JCV encephalopathy, and even isolated JCV meningitis¹¹. In GCN, the granule cell neurons of the cerebellum are affected, resulting in symptoms including ataxia, tremor, and nystagmus¹². JCV encephalopathy is pathologically characterized by the infection and lysis of the cortical gray matter¹³.

Diagnosis of PML

The diagnosis of PML requires clinical, radiographic, and virologic evidence⁵. Clinically, PML can present with a wide constellation of neurologic signs and symptoms due to its ability to affect virtually any area of the brain and the frequently multifocal nature of the lesions. In patients with multiple sclerosis (MS) on natalizumab or other disease-modifying drugs that seem to predispose to PML, distinguishing PML from an acute MS attack can be difficult, as the general symptoms can be similar to the symptoms of an MS flare. The most commonly reported symptoms include gait changes, weakness, cognitive impairment, sensory symptoms, headache, and visual changes¹⁴. Visual symptoms are reported in one-quarter to one-half of all PML patients, typically presenting as a field deficit, and can be the initial symptom as well¹⁵. Visual system involvement is secondary to involvement of the visual pathways and not as a direct optic neuritis, as seen in other inflammatory, demyelinating diseases¹⁵.

Seizures can occur in up to one-third of the general PML population and are more frequent with juxtacortical and T1-hyperintense lesions by magnetic resonance imaging (MRI)¹³. There is subtle variation in the presentation of PML as determined by the underlying cause: HIV-associated PML vs. immunosuppressant-associated PML. Unlike PML associated with HIV infection where 50% have predominant motor system findings⁷, natalizumab-associated PML appears to be more commonly associated with cognitive and language changes; motor symptoms are reported in only one-third of natalizumab PML patients¹⁴.

Pathologically, PML is characterized by multifocal demyelination, with smaller lesions coalescing into larger foci. Overall lesion burden can be extensive, involving entire hemispheres, and can occur throughout the white matter. By histopathology, PML is characterized by multifocal demyelination, enlarged astrocytes that contain lobulated hyperchromatic nuclei and oligodendrocytic hyperpigmented enlarged nuclei¹⁶. JC virions can be found by electron microscopy, particularly within reactive astrocytes.

The appearance of PML by cerebral imaging can be heterogeneous, although it is typically multifocal with frontal or parieto-occipital locations predominating. There are rare reports of PML involvement isolated to the deep gray matter or the brainstem, or

even resulting in spinal cord parenchyma abnormalities, but, to date, clinical features of a myelopathy have not been reported with PML¹⁷. On computed tomography (CT) imaging, PML lesions are hypointense within the white matter. When the subcortical arcuate fibers are involved, the lesions can have a ‘scalloped’ appearance. By MRI, a far more sensitive measure to detect evidence of PML, lesions are hyperintense by T2 and fluid-attenuated inversion recovery (FLAIR) imaging and hypointense by T1. Gadolinium enhancement is more common in natalizumab cases, one-third vs. 15% of HIV-associated cases¹⁴. Of note, similar radiographic patterns can also be found in cytomegalovirus infections, acute disseminated encephalomyelitis, varicella-zoster leukoencephalopathy, and brain tumors, although the diagnosis is often evident within the context of a full history and physical examination¹⁴. Patients prescribed medications such as natalizumab should be annually screened by MRI for the imaging characteristics of PML, as it is possible to detect the radiographic findings before the clinical onset.

To develop PML, a patient must have a latent or persistent infection with the JCV. This is believed to be in an extraneural reservoir, chiefly the kidney. The virus then undergoes genetic rearrangement into the neurotropic form, infects oligodendrocytes and astrocytes within the CNS, and leads to demyelination from oligodendrocyte lysis when the host cannot mount an appropriate immune response to contain the virus. The value of cerebrospinal fluid (CSF) polymerase chain reaction (PCR) for JCPyV is highly dependent on the nature of the test; ultrasensitive PCR techniques for JCPyV have a sensitivity of >95%. Patients on natalizumab at risk for the development of PML are typically screened for the presence of JCV-specific antibodies. A semi-quantitative antibody index is used to indirectly track JC infection and prognosticate PML risk. JCV antibody index exceeding 1.5 has been associated with a higher risk of PML¹⁸. Other factors significantly increasing the risk for natalizumab-associated PML is prior immunosuppressive therapy use and duration of natalizumab (>24 months) therapy¹⁹.

PML survival and treatment

PML is an aggressive, potentially fatal disease. In individuals in whom the immune dysfunction can be restored, such as patients with AIDS in whom immune function is restored by antiretroviral therapy, survival is improved²⁰. Presumably, the same is true of patients on immunosuppressive agents, such as natalizumab, who are diagnosed early and treated with drug cessation, plasma exchange to more quickly eliminate the natalizumab, and supportive care^{4,14,21}. Mortality in natalizumab-related cases is approximately 21%^{22,23}. Survival in the natalizumab cases was associated with younger age, lower pre-PML functional disability, lower viral loads, and more focal brain involvement²³. Survival in HIV-associated PML cases is dependent on CD4 count and ranges from 50% to 80%²¹. PML may be associated with the immune reconstitution syndrome (IRIS) with recovery of immune function. IRIS is defined as a worsening of radiographic and clinical findings of an infection in the context of immune system recovery. Accordingly, patients are often treated with corticosteroids concurrent with supportive care and plasma exchange, although the benefit of this approach still remains unproven⁹. Among natalizumab-associated PML survivors, one-third of the patients have mild neurologic deficits, one-third

have moderate impairment, and one-third are severely affected^{22,24}. Despite the efficacy of certain therapeutic agents in decreasing JCPyV replication *in vitro*, such as mefloquine and cidofovir, none have demonstrated efficacy in randomized controlled trials.

In conclusion, PML is an aggressive brain infection caused by the JCV, almost exclusively found in immunosuppressed patients. Although consensus is that high-risk patients on immunosuppressant medications such as natalizumab should be monitored by serial imaging and anti-JCV antibody screening, the frequency of testing and the threshold for concern is a rapidly moving target. The mainstays of treatment include stopping the inciting agent and plasma exchange, although directed anti-viral therapeutics is an active area of investigation. While the duration of therapy with natalizumab influences the risk, many other factors are involved in the development of PML, suggesting a complexity to the predisposition to PML development.

Abbreviations

AIDS - Acquired immunodeficiency syndrome
PML - Progressive multifocal leukoencephalopathy
HIV - Human immunodeficiency virus
CNS - Central nervous system
CT - Computed tomography
IRIS - Immune reconstitution syndrome
JC - John Cunningham
JCV - John Cunningham virus
JCPyV - John Cunningham polyomavirus
MRI - Magnetic resonance imaging
HAART - Highly active antiretroviral therapy
VCAM - Vascular cell adhesion molecule 1
GCN - Granule cell neuronopathy
MS - Multiple sclerosis
CSF - Cerebrospinal fluid
PCR - Polymerase chain reaction

Competing interests

Laura Adang declares that she has no competing interests.

Joseph R. Berger is or has been a consultant to the following companies: Genentech, Genzyme, Incyte, Inhibikase, Johnson & Johnson, and Novartis. He serves or has served on the PML Adjudication Committees of the following companies: Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen, Millennium, PAREXEL, Pfizer, Roche, and Takeda.

Grant information

Joseph R. Berger has received grants from the PML Consortium and Biogen Idec.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Astrom KE, Mancall EL, Richardson EP Jr: **Progressive multifocal leukoencephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.** *Brain.* 1958; **81**(1): 93–111.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Padgett BL, Walker DL, ZuRhein GM, *et al.*: **Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy.** *Lancet.* 1971; **1**(7712): 1257–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. White MK, Khalili K: **Pathogenesis of progressive multifocal leukoencephalopathy--revisited.** *J Infect Dis.* 2011; **203**(5): 578–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Engsig FN, Hansen AB, Omland LH, *et al.*: **Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.** *J Infect Dis.* 2009; **199**(1): 77–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Berger JR, Aksamit AJ, Clifford DB, *et al.*: **PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.** *Neurology.* 2013; **80**(15): 1430–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Bozic C, Subramanyam M, Richman S, *et al.*: **Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.** *Eur J Neurol.* 2014; **21**(2): 299–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Berger JR, Pall L, Lanska D, *et al.*: **Progressive multifocal leukoencephalopathy in patients with HIV infection.** *J Neurovirol.* 1998; **4**(1): 59–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Zaheer F, Berger JR: **Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.** *Ther Adv Drug Saf.* 2012; **3**(5): 227–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Williamson EM, Berger JR: **Infection risk in patients on multiple sclerosis therapeutics.** *CNS Drugs.* 2015; **29**(3): 229–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. O'Connor P, Miller D, Riestler K, *et al.*: **Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.** *Mult Scler.* 2005; **11**(5): 568–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Gheuens S, Wüthrich C, Koralnik IJ: **Progressive multifocal leukoencephalopathy: why gray and white matter.** *Annu Rev Pathol.* 2013; **8**: 189–215.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
12. Henry C, Jouan F, De Broucker T: **JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration.** *J Neurol Sci.* 2015; **354**(1–2): 86–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
13. Khoury MN, Alsop DC, Agnihotri SP, *et al.*: **Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy.** *Ann Neurol.* 2014; **75**(5): 659–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
14. Berger JR: **Progressive multifocal leukoencephalopathy.** *Handb Clin Neurol.* 2014; **123**: 357–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Sudhakar P, Bachman DM, Mark AS, *et al.*: **Progressive Multifocal Leukoencephalopathy: Recent Advances and a Neuro-Ophthalmological Review.** *J Neuroophthalmol.* 2015; **35**(3): 296–305.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Woodhouse MA, Dayan AD, Burston J, *et al.*: **Progressive multifocal leukoencephalopathy: electron microscope study of four cases.** *Brain.* 1967; **90**(4): 863–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Murayi R, Schmitt J, Woo JH, *et al.*: **Spinal cord progressive multifocal leukoencephalopathy detected pre-mortem by MRI.** *J Neurovirol.* 2015; **21**(6): 688–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Plavina T, Subramanyam M, Bloomgren G, *et al.*: **Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.** *Ann Neurol.* 2014; **76**(6): 802–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
19. Bloomgren G, Richman S, Hotermans C, *et al.*: **Risk of natalizumab-associated progressive multifocal leukoencephalopathy.** *N Engl J Med.* 2012; **366**(20): 1870–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
20. Antinori A, Ammassari A, Giancola ML, *et al.*: **Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era.** *J Neurovirol.* 2001; **7**(4): 323–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
21. Casado JL, Corral I, García J, *et al.*: **Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.** *Eur J Clin Microbiol Infect Dis.* 2014; **33**(2): 179–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
22. Vermersch P, Kappos L, Gold R, *et al.*: **Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.** *Neurology.* 2011; **76**(20): 1697–704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. Dong-Si T, Gheuens S, Gangadharan A, *et al.*: **Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.** *J Neurovirol.* 2015; **21**(6): 637–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. Lima MA, Bernal-Cano F, Clifford DB, *et al.*: **Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy.** *J Neurol Neurosurg Psychiatr.* 2010; **81**(11): 1288–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Meena Subramanyam**

Biogen Idec, Cambridge, Massachusetts, 02142, USA

Ellen Cahir-McFarland

Biogen Idec, Cambridge, Massachusetts, 02142, USA

Competing Interests: No competing interests were disclosed.

2. **Stephen G. Waxman**

Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University, New Haven, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research